Vascor

arthrography, peripheral arteriography, intravenous excretory urography + 11 more

Treatment

13 FDA approvals

20 Active Studies for Vascor

What is Vascor

Iothalamic acid

The Generic name of this drug

Treatment Summary

Iothalamic acid is a medical agent containing iodine that is used to help identify and diagnose medical issues.

Glofil-125

is the brand name

Vascor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Glofil-125

Iothalamic acid

1983

7

Approved as Treatment by the FDA

Iothalamic acid, otherwise called Glofil-125, is approved by the FDA for 13 uses which include Kidney Diseases and peripheral arteriography .

Kidney Diseases

peripheral arteriography

Bone structure of cranium

computerized tomography

venography

Chronic Kidney Disease (CKD)

Glomerular Filtration Rate (GFR)

arthrography

cerebral angiography

Endoscopic Retrograde Cholangiopancreatography

Cholangiography

angiogram

intravenous excretory urography

When to interrupt dosage

The proposed dose of Vascor is contingent upon the diagnosed condition, including cerebral angiography, venography and cystourethrography. The measure of dosage shifts in accordance with the technique of delivery (e.g. Solution or Intra-arterial; Intravenous) featured in the table beneath.

Condition

Dosage

Administration

arthrography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

peripheral arteriography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

intravenous excretory urography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

venography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

computerized tomography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

cerebral angiography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

retrograde cystography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

angiogram

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Bone structure of cranium

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Chronic Kidney Disease (CKD)

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Endoscopic Retrograde Cholangiopancreatography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Glomerular Filtration Rate (GFR)

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

cystourethrography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Cholangiography

, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL

Intravenous, , Injection, solution, Injection, solution - Intravenous, Intravascular, Solution - Intravascular, Solution, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Solution - Intra-arterial; Intravenous, Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection - Ureteral, Injection, Injection - Intravascular, Injection - Intravenous

Warnings

Vascor Contraindications

Condition

Risk Level

Notes

myelography

Do Not Combine

Pancreatitis

Do Not Combine

Prothrombin time prolongation

Do Not Combine

Endoscopy (procedure)

Do Not Combine

infection near the joint

Do Not Combine

Blood Coagulation Disorders

Do Not Combine

Cholangitis

Do Not Combine

There are 20 known major drug interactions with Vascor.

Common Vascor Drug Interactions

Drug Name

Risk Level

Description

Acrivastine

Minor

Iothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Iothalamic acid may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Almasilate

Minor

Iothalamic acid may decrease the excretion rate of Almasilate which could result in a higher serum level.

Antihemophilic factor (recombinant), PEGylated

Minor

Iothalamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.

Antithrombin III human

Minor

Iothalamic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.

Vascor Novel Uses: Which Conditions Have a Clinical Trial Featuring Vascor?

At present, 236 active clinical trials are assessing the effectiveness of Vascor in venography, Glomerular Filtration Rate (GFR) and angiogram.

Condition

Clinical Trials

Trial Phases

cystourethrography

0 Actively Recruiting

peripheral arteriography

0 Actively Recruiting

Endoscopic Retrograde Cholangiopancreatography

0 Actively Recruiting

cerebral angiography

0 Actively Recruiting

Bone structure of cranium

0 Actively Recruiting

Chronic Kidney Disease (CKD)

28 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

intravenous excretory urography

0 Actively Recruiting

angiogram

0 Actively Recruiting

Glomerular Filtration Rate (GFR)

0 Actively Recruiting

Cholangiography

0 Actively Recruiting

venography

0 Actively Recruiting

computerized tomography

1 Actively Recruiting

Phase 2

retrograde cystography

0 Actively Recruiting

arthrography

0 Actively Recruiting

Patient Q&A Section about vascor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who owns VASCOR ltd?

"VASCOR is a privately held joint venture between APL Logistics and Fujitrans Corporation. It is infused with expertise that comes from the connection to its owners' global supply chain solutions in more than 50 countries across six continents, which includes overseas subsidiaries and partners."

Answered by AI

Who manufactures vascor?

"The text is talking about the joint venture between two companies, APL Logistics and Fujitrans Corporation."

Answered by AI

Clinical Trials for Vascor

Image of Columbia University in New York, United States.

MediBeacon Transdermal GFR System for Heart Failure

18+
All Sexes
New York, NY

The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance measurement of GFR in adults with heart failure. The main question it aims to answer is the comparison of the transdermal-derived GFR for each participant using the MediBeacon tGFR to their nGFRBSA measurement. Participants will participate in a Screening visit that will take place within 15 days of the scheduled administration of Lumitrace and iohexol. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and iohexol and the initiation of GFR assessments, participants will be followed at the study center for 10-24 hours. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace and iohexol. Researchers will analyze the results to compare the tGFR values to the nGFRBSA measurements for each participant.

Waitlist Available
Has No Placebo

Columbia University

Richard B Dorshow, PhD

MediBeacon

Image of Fletcher Allen Health Care, University of Vermont Medical School in Burlington, United States.

Protein Loading for Kidney Function Assessment

18+
All Sexes
Burlington, VT

The goal of this clinical trial is to evaluate the effect of protein loading on the measurement of renal reserve using the MediBeacon Transdermal glomerular filtration rate (tGFR) system. Adults with estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73 m\^2 will be recruited to join the study. This is a potential new use for the tGFR for the assessment of renal reserve. Renal reserve is the increase in GFR that occurs in response to various stimuli, such as when one kidney is removed. The remaining kidney will often show an increase in GFR to compensate. Renal reserve is typically measured after a high protein meal and requires a reproducible stimulus and a repeated measurement of GFR. The main questions it aims to answer are: * To characterize the effect of protein loading on GFR (dose response curve) as assessed by the MediBeacon Transdermal GFR System * To determine Renal Reserve in participants with chronic kidney disease (CKD) using the MediBeacon Transdermal GFR System * To demonstrate whether any change in GFR following the protein stimulus is associated with a change in cardiac output using non-invasive bioimpedance (NICaS) Participants will participate in a Screening visit that will take place within 28 days of the scheduled administration of Lumitrace. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and the initiation of GFR assessments, participants will ingest a high protein meal over 15-20 minutes. They will be followed at the study center for up to 6-8 hours following administration of Lumitrace. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace. Researchers will analyze the results to see if there is a detectable difference in fluorescence clearance rate following the high protein meal.

Waitlist Available
Has No Placebo

Fletcher Allen Health Care, University of Vermont Medical School

Richard B Dorshow, PhD

MediBeacon

Have you considered Vascor clinical trials?

We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Inspire HER for Cardiovascular Disease

30 - 79
Female
Birmingham, AL

Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.

Recruiting
Has No Placebo

University of Alabama at Birmingham

Timiya S Nolan, PhD

Have you considered Vascor clinical trials?

We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Francisco School of Medicine in San Francisco, United States.

Valganciclovir for Cytomegalovirus Infection

18+
All Sexes
San Francisco, CA

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per Food and Drug Administration (FDA) label\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study. Estimated Time to Complete Enrollment: 4 years

Phase 3
Recruiting

University of California, San Francisco School of Medicine (+4 Sites)

Abhijit P. Limaye, MD

Have you considered Vascor clinical trials?

We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Go to Trials